NCT04135261已完成1 期
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 17
- 主要终点
- Part 1: Proportion of subjects with Dose-Limiting Toxicity (DLT)
研究概览
简要总结
This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. The study will also look at the anti-tumor activity of HBM4003.The study consists of 2 parts. In Part 1, patients are enrolled into different cohort doses in order to identify the appropriate recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD). In Part 2, participants with metastatic/unresectable melanoma will receive the MTD and/or RP2D established in Part 1 of the study. In Part 1 and Part 2, participants will be administered treatment either once per week or once every 3 weeks.
NOTE: Participants are no longer being recruited to this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form and willingness to comply with study requirements.
- •Part 1 (Dose-escalation): Adult subject ≤ 75 years old with confirmed advanced solid tumors that have progressed after treatment with standard therapies, or for which no effective standard therapy is available, or the subject refuses or has a contraindication to standard therapy.
- •Part 2 (Dose-expansion)
- •Adult subjects 18 years and above.
- •Melanoma Cohort:
- •Histologically confirmed metastatic or unresectable melanoma that progressed during or after treatment with a PD-1 inhibitor (excluding bi-specific antibody) with CTLA-4 blocking function.
- •Must have received at least one BRAF inhibitor with/without a MEK inhibitor if positive with BRAF V600-activating mutation.
- •HCC Cohort:
- •Histologically confirmed metastatic or unresectable hepatocellular carcinoma;
- •Child-Pugh Score of 6 points or less (A5-A6);
- •Patient with HBV infection will be allowed if he/she is receiving appropriate antiviral therapy for hepatitis B virus (HBV) according to institutional standard of care and HBV DNA level is < 2000 UI/mL;
- •Patient with HCV infection will be allowed if he/she is receiving appropriate antiviral therapy for hepatitis C virus (HCV) according to institutional standard of care and HCV antibody returns to negative;
- •Have received at least one anti-VEGF treatment (either anti-VEGFR TKI or anti-VEGF monoclonal antibody) and/or anti-PD-(L)1 treatment.
- •RCC Cohort:
- •Histologically confirmed metastatic or unresectable renal cell cancer (including both clear cell and non-clear histology);
- •Subjects with clear cell RCC must have failed at least 1 anti-VEGFR TKI treatment and/or anti-PD(L)1 treatment;
- •For subjects with non-clear cell RCC (e.g. PRCC), treatment naive is permitted.
- •Must have at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.
- •Willing to undergo tumor biopsy unless determined medically unsafe or not feasible.
- •For subjects whose last treatment was immunotherapy, must have disease progression confirmed at least 4 weeks after the initial radiographic evidence of progression;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Adequate organ and bone marrow function.
- •Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of HBM4003; and have a negative serum pregnancy test.
- •Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.
- •Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.
- •Life expectancy of ≥12 weeks.
排除标准
- •Part 1 and Part 2
- •History of severe or not under well controlled allergic diseases, history of severe drug allergy, or are known to be allergic to macromolecular protein preparations or any component of the study drug.
- •Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of the study drug:
- •CTLA-4 antibody any time prior to study drug administration;
- •Any PD-1 or PD-L1 or Programmed cell death protein ligand 2 (PDL2)-directed antibody within 8 weeks of study drug administration;
- •Any cancer vaccines within 3 months prior to first dose of study drug;
- •Live vaccine within 4 weeks prior to first dose of study drug;
- •Any other anticancer therapy within 2 weeks prior to first dose of study drug.
- •Not yet recovered from surgery within 28 days prior to first dose of HBM4003 or (immune-related) toxicity related with previous treatment.
- •Concomitant medication or treatments:
- •Any concurrent chemotherapy, radiotherapy, immunotherapy, or biological therapy for cancer treatment. Concurrent use of hormones on a stable dose for non-cancer related conditions is acceptable. Androgen deprivation therapy (ADT) for advanced prostate cancers is acceptable. Local treatment of isolated non-target lesions for palliative intent is acceptable;
- •Any traditional anti-tumor herbal medications;
- •Receipt of red blood cells or platelets infusion, granulocyte colony stimulating factor (G-CSF) or granulocyte monocyte colony stimulating factor (GM-CSF) within 1 week of the first dose of HBM
- •Corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 2 weeks of study drug administration; Nasal spray, inhalation, topical corticosteroids or physiological doses of systemic corticosteroids are not included.
- •Have other diseases that may affect the effectiveness and safety of the study drug, such as:
- •Known brain metastases or other central nervous system metastases that is either symptomatic or untreated, that requires concurrent treatment;
- •Active infection requiring treatment with antibiotics within 14 days prior to first dose of HBM4003;
- •Known history of infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus 1, hepatitis B virus, or active hepatitis C virus;
- •Suspected autoimmune disease, including but not limited to inflammatory bowel disease, autoimmune hepatitis, Guillain-Barre syndrome.
- •Known primary immunodeficiency;
- •Clinically significant gastrointestinal disorders (e.g. diarrhea with significant clinical meaning), active gastrointestinal bleeding, or a history of gastrointestinal perforation, acute diverticulitis, intra-abdominal abscess or gastrointestinal obstruction;
- •Have received allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or have received autologous hematopoietic stem cell transplantation within 3 months prior to the first dose of study drug.
- •Subjects with medically confirmed autoimmune coeliac disease are to be excluded. Patients with so-called gluten intolerance or other conditions labelled "coeliac disease" which are not autoimmune in nature and which are well controlled by diet should be medically confirmed as non-autoimmune "coeliac disease" and can be considered for study.
- •Subjects with major cardiovascular disease.
- •History of other uncured malignant diseases, except for non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ that has been curatively resected, and localized prostate cancer managed by active surveillance.
- •Pregnant or breastfeeding women.
- •Have experienced immune-related GI adverse events on any prior immunotherapy or toxicity that led to permanent discontinuation of prior immunotherapy.
- •Severe cirrhosis, hepatic atrophy, portal hypertension.
- •Main portal vein thrombosis present on imaging.
- •Any prior or current clinically significant ascites (moderate to massive with significantly abnormal liver function).
- •Any history of hepatic encephalopathy within 12 months prior to randomization or require medications to prevent or control encephalopathy.
- •Subjects weighting < 30 kg.
- •Active or prior documented GI bleeding (e.g. esophageal varices or ulcer bleeding) within 12 months.
- •Additional criterial for HCC cohort:
- •Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- •Prior liver transplantation.
- •HBV and HCV co-infection, HBV and HEV co-infection, HBV and HDV co-infection.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
Part 1: Dose escalation
Experimental
QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)
Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee.
干预措施: HBM4003 (Drug)
Part 2: Dose expansion
Experimental
Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
干预措施: HBM4003 (Drug)
结局指标
主要结局
Part 1: Proportion of subjects with Dose-Limiting Toxicity (DLT)
时间窗: From Day 1 until disease progression or Day 28, whichever comes first
Number of subjects who experience DLT events during 28 days (if on QW dosing schedule) or 21 days (if on Q3W dosing schedule)
Part 2: Objective Response Rate (ORR)
时间窗: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.
Proportion of subjects with best overall response of complete response (CR) or partial response (PR) per RECIST 1.1
次要结局
- Part 1: Objective Response Rate(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 1: Duration of response(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 1: Disease control rate(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 1: Cmax (Maximum serum concentration)(Up to 80 days after end of treatment)
- Part 1: Rac(AUC0-tau)(Up to 80 days after end of treatment)
- Part 1: Duration of disease control(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 1: Tumor shrinkage (The percentage of patients with tumor shrinkage)(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 1: Tmax (Time to reach maximum serum concentration)(Up to 80 days after end of treatment)
- Part 1: AUC0-inf (Area under the serum concentration versus time curve from time zero to infinity(Up to 80 days after end of treatment)
- Part 1: t1/2 (Terminal half-life)(Up to 80 days after end of treatment)
- Part 1: Clearance (CL)(Up to 80 days after end of treatment)
- Part 1: Cmin (Minimum serum concentration)(Up to 80 days after end of treatment)
- Part 1: Rac(Cmax)(Up to 80 days after end of treatment)
- Part 1: Vss (Volume of distribution at steady state)(Up to 80 days after end of treatment)
- Part 1: AUC0-tau (Area under the serum concentration versus time curve from time zero to the dosing interval tau(Up to 80 days after end of treatment)
- Part 2: Disease control rate(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 2: Duration of objective response(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 2: Objective Response Rate(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 2: Duration of disease control(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
- Part 2: Tumor shrinkage (The percentage of patients with tumor shrinkage)(Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05824663Harbour BioMed US, Inc.17
已完成
1 期
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerProstate CancerNCT04087174AstraZeneca27
已完成
1 期
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaHepatocellular Carcinoma MetastaticNCT01839604AstraZeneca58
进行中（未招募）
1 期
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDACMetastatic Pancreatic CancerNCT06059001Peptomyc S.L.26
招募中
1 期
A Study of SHR-4602 in Subjects With Advanced Malignant Solid TumorsAdvanced Solid TumorNCT05819684Suzhou Suncadia Biopharmaceuticals Co., Ltd.133